Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MBRX

+ Watchlist+ Portfolio

Moleculin Biotech, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$6.75
52-Week Range
$3.22 – $227.00
Market Cap
$8.42M
P/E (TTM)
0.04
EPS (TTM)
179.60
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.57
PEG Ratio
—
Return on Equity
—
Return on Assets
-89.99%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
1.37
Debt/Equity
0.01
Total Debt
$107.00K
Free Cash Flow
$-17.26M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-14.65K

Market Snapshot

About

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing oncology drug candidates for resistant and difficult-to-treat tumors. The company focuses on novel anti-tumor agents targeting highly refractory cancers, including glioblastoma, pancreatic cancer, and acute myeloid leukemia. Their pipeline includes small molecules designed to disrupt multiple tumor defense mechanisms simultaneously.